{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T04:16:17Z","timestamp":1750997777057,"version":"3.41.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.esmogo.2025.100173","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T11:54:40Z","timestamp":1748346880000},"page":"100173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Intra-arterial hepatic chemotherapy in metastatic colorectal cancer: differences between oxaliplatin-naive versus oxaliplatin-pretreated patients"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9193-986X","authenticated-orcid":false,"given":"E.","family":"El Rawadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1061-321X","authenticated-orcid":false,"given":"B.","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Pierotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Boige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8878-4916","authenticated-orcid":false,"given":"L.","family":"Tselikas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Smolenschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7787-6911","authenticated-orcid":false,"given":"M.","family":"Val\u00e9ry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6591-2213","authenticated-orcid":false,"given":"T.","family":"Pudlarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Fuerea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"De Baere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3804-3554","authenticated-orcid":false,"given":"A.","family":"Tarabay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Fernandez-de-Sevilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7664-0130","authenticated-orcid":false,"given":"D.","family":"Malka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-7551","authenticated-orcid":false,"given":"A.","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Boil\u00e8ve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.esmogo.2025.100173_bib1","first-page":"89","article-title":"Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors","volume":"14","author":"Rawla","year":"2019","journal-title":"Przegl\u0105d Gastroenterol"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100173_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.esmogo.2025.100173_bib3","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/01.sla.0000141198.92114.f6","article-title":"Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival","volume":"240","author":"Adam","year":"2004","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.esmogo.2025.100173_bib4","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.surg.2018.01.004","article-title":"Actual 10-year survival following hepatic resection of colorectal liver metastases: what factors preclude cure?","volume":"163","author":"Creasy","year":"2018","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100173_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1200\/JOP.2015.009407","article-title":"Surgical management of liver metastases from colorectal cancer","volume":"12","author":"Dhir","year":"2016","journal-title":"J Oncol Pract"},{"issue":"5","key":"10.1016\/j.esmogo.2025.100173_bib6","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jamcollsurg.2009.12.040","article-title":"Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution","volume":"210","author":"House","year":"2010","journal-title":"J Am Coll Surg"},{"issue":"4","key":"10.1016\/j.esmogo.2025.100173_bib7","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/cncr.22448","article-title":"Survival after hepatic resection in metastatic colorectal cancer: a population-based study","volume":"109","author":"Cummings","year":"2007","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.esmogo.2025.100173_bib8","first-page":"969","article-title":"The blood supply of neoplasms in the liver","volume":"30","author":"Breedis","year":"1954","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.esmogo.2025.100173_bib9","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/annonc\/mdg247","article-title":"Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer","volume":"14","author":"Fallik","year":"2003","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmogo.2025.100173_bib10","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.1984.2.5.498","article-title":"Pharmacologic rationale for regional drug delivery","volume":"2","author":"Collins","year":"1984","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmogo.2025.100173_bib11","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.3390\/cancers13123091","article-title":"Hepatic arterial infusion of chemotherapy for advanced hepatobiliary cancers: state of the art","volume":"13","author":"Laface","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.esmogo.2025.100173_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007823","article-title":"Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer","author":"Mocellin","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.esmogo.2025.100173_bib13","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/1097-0142(19920115)69:2<327::AID-CNCR2820690209>3.0.CO;2-U","article-title":"A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer","volume":"69","author":"Kemeny","year":"1992","journal-title":"Cancer"},{"issue":"22","key":"10.1016\/j.esmogo.2025.100173_bib14","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1200\/JCO.2005.05.120","article-title":"Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer","volume":"23","author":"Ducreux","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmogo.2025.100173_bib15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdv548","article-title":"Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV","volume":"27","author":"L\u00e9vi","year":"2016","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmogo.2025.100173_bib16","article-title":"Chimioth\u00e9rapie intra-art\u00e9rielle h\u00e9patique: un apport importantpour le traitement des m\u00e9tastases h\u00e9patiques des cancers colorectaux - Actualit\u00e9s aux 26es FFCD","author":"Pernot","year":"2015","journal-title":"La Lettre de l\u2019H\u00e9pato-gastroent\u00e9rologue"},{"issue":"suppl 16","key":"10.1016\/j.esmogo.2025.100173_bib17","article-title":"Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a multicenter randomized phase II trial (PRODIGE 43 - PACHA-01)","volume":"41","author":"Gelli","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmogo.2025.100173_bib18","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/SLA.0b013e3181d35983","article-title":"Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases","volume":"251","author":"Go\u00e9r\u00e9","year":"2010","journal-title":"Ann Surg"},{"issue":"21","key":"10.1016\/j.esmogo.2025.100173_bib19","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1200\/JCO.2008.20.1301","article-title":"Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma","volume":"27","author":"Kemeny","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmogo.2025.100173_bib20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/SLA.0000000000000614","article-title":"Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes","volume":"261","author":"D\u02bcAngelica","year":"2015","journal-title":"Ann Surg"},{"issue":"16","key":"10.1016\/j.esmogo.2025.100173_bib21","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1200\/JCO.2012.44.8308","article-title":"Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases","volume":"31","author":"Ye","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmogo.2025.100173_bib22","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/annonc\/mdu580","article-title":"Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial","volume":"26","author":"Gruenberger","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmogo.2025.100173_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/S0923-7534(20)33192-6","article-title":"Hepatic arterial infusion (HAI) of oxaliplatin plus intravenous (IV) fluorouracil (FU), leucovorin (LV) and cetuximab for first-line treatment of unresectable colorectal liver metastases (CRLM): final results of a multicenter phase 2 study (CHOICE)","volume":"23","author":"Malka","year":"2012","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmogo.2025.100173_bib24","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/jso.24399","article-title":"Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies","volume":"114","author":"Cercek","year":"2016","journal-title":"J Surg Oncol"},{"issue":"1","key":"10.1016\/j.esmogo.2025.100173_bib25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1245\/s10434-007-9581-7","article-title":"Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure","volume":"15","author":"Boige","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.esmogo.2025.100173_bib26","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1007\/s00330-024-10887-1","article-title":"Safety and efficacy of percutaneous arterial port Implantation for Hepatic Arterial Infusion Chemotherapy","volume":"35","author":"Meyblum","year":"2025","journal-title":"Eur Radiol"},{"issue":"9","key":"10.1016\/j.esmogo.2025.100173_bib27","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.ejca.2014.02.024","article-title":"Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer","volume":"50","author":"Jones","year":"2014","journal-title":"Eur J Cancer"},{"issue":"29","key":"10.1016\/j.esmogo.2025.100173_bib28","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1200\/JCO.2007.10.8126","article-title":"Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy","volume":"5","author":"Adam","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmogo.2025.100173_bib29","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/annonc\/mdm405","article-title":"Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis","volume":"18","author":"Gallagher","year":"2007","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmogo.2025.100173_bib30","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1245\/s10434-013-3275-0","article-title":"Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab","volume":"21","author":"Cercek","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.esmogo.2025.100173_bib31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejca.2020.07.022","article-title":"Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases","volume":"138","author":"Boil\u00e8ve","year":"2020","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.esmogo.2025.100173_bib32","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.dld.2021.12.012","article-title":"Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +\/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49","volume":"54","author":"Pernot","year":"2022","journal-title":"Dig Liver Dis"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819825000421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819825000421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:16:07Z","timestamp":1750983367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819825000421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":32,"alternative-id":["S2949819825000421"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2025.100173","relation":{},"ISSN":["2949-8198"],"issn-type":[{"type":"print","value":"2949-8198"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intra-arterial hepatic chemotherapy in metastatic colorectal cancer: differences between oxaliplatin-naive versus oxaliplatin-pretreated patients","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2025.100173","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100173"}}